Sleep apnea specialist, ResMed, is launching its ResMed Air Solutions range, which it says allows a patient’s breathing during sleep to be intelligently stabilised and monitored.
Around 14 million people in Europe are thought to be currently living with heart failure, with 30-50% of these at risk of having concurrent central sleep-disordered breathing.
Resmed has been pioneering new and innovative devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease, and other key chronic diseases for more than 25 years. The newest offering to come from its stable is the ResMed Air Solutions range, led by the intelligent, cloud-enabled AirCurve 10 CS PaceWave™ with AirView system. In a press release Resmed says this is the first device to combine remote monitoring with ResMed’s innovative PaceWave™ Minute Ventilation (MV)-Adaptive-Servo-Ventilation (ASV) therapy. Through a unique patented algorithm, PaceWave MV-ASV allows a patient’s breathing during sleep to be intelligently stabilised and monitored, offering an option to treat a wide variety of patients with central sleep apnoea (CSA), a specific form of sleep-disordered breathing. This is especially relevant for those suffering from Cheyne-Stokes Respiration (CSR), a pattern of CSA commonly seen in patients with heart failure and thought to affect up to 50% of patients with chronic heart failure, being linked to increased mortality and morbidity in this patient population.
The use of PaceWave MV-ASV therapy to treat CSA in patients with chronic heart failure is currently being investigated in SERVE-HF, the world’s largest randomised trial in this field. SERVE-HF is the world’s largest randomised study to investigate if treating chronic heart failure patients who also have CSA with PaceWave MV-ASV therapy may improve outcomes including mortality and morbidity. More than 1,325 patients have taken part in the study, which completed enrolment in 2013.
ResMed says its AirCurve 10 CS PaceWave™ is now available in select European countries.
Anne Reiser, President of ResMed Europe and Asia Pacific, said: “The launch of Air Solutions and the unique offering of the AirCurve 10 CS PaceWave with AirView represents a landmark shift in the treatment of central sleep apnea. By combining ResMed-patented technology with new wireless monitoring capabilities, we are providing a solution that is both an effective therapy, and has potential to offer significant time and cost savings to physicians and health services.
“This launch may also have significant implications for many patients with chronic heart failure. The findings of the SERVE-HF study will indicate the scale of benefit PaceWave MV-ASV may bring but there is real potential for a step-change on how we prioritise breathing management in this patient population.”
Source: Business Wire